Last checked at 17 Jul 2020 09:14
VALIRX PLC
("ValiRx", the "Company" or the "Group")
AGM Arrangements
The Company's Annual General Meeting ("AGM") is due to be held on Thursday 23rd July 2020 at 12pm. As set out in the Notice of Annual General Meeting ("Notice") due to the Covid-19 pandemic and associated restrictions on public gatherings, shareholders are encouraged to vote by proxy and not to attend the meeting.
The Board notes that recent legislation permits virtual shareholder meetings to be held during the pandemic and so will arrange for a quorum comprising at least two shareholder-directors to conduct the meeting remotely. Accordingly, under the legislation, the Board intends for the AGM to be held electronically and not in person by the shareholder-directors and so no one will be present at the location identified in the Notice at the appointed time and shareholders are urged not to attend the AGM in person.
The latest date for receipt of proxies is Tuesday 21st July 2020 at 12pm in accordance with the procedure set forth in the Notice. The result of the proxy votes will be announced after the AGM in the usual way. There is also a procedure in the Notice pursuant to which shareholders may ask questions in writing and the Board will respond in due course.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 7073 2628 www.valirx.com |
Suzanne Dilly | Suzanne.Dilly@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker | Tel: +44 (0) 20 7469 0930 |
Notes for Editors
About ValiRx
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.